Sac/val efficacy, compared with enalapril, an angiotensin-converting enzyme (ACE) inhibitor, was evaluated in the PARADIGM-HF randomized controlled trial [6,7,8,9], finding a significant reduction in re-hospitalizations for HF and risk of cardiovascular mortality compared with people living with HF treated with the ACE inhibitor. The gene discussed is ACE; the disease is hydrops fetalis.